Regulations Amending the Cannabis Regulations (Harmonization with Certain Provisions of the Controlled Substances Regulations): SOR/2025-244

Canada Gazette, Part II, Volume 159, Number 26

Registration
SOR/2025-244 November 28, 2025

CANNABIS ACT

P.C. 2025-842 November 28, 2025

Her Excellency the Governor General in Council, on the recommendation of the Minister of Health, makes the annexed Regulations Amending the Cannabis Regulations (Harmonization with Certain Provisions of the Controlled Substances Regulations) under subsection 139(1) of the Cannabis Act ^{footnote a}.

Regulations Amending the Cannabis Regulations (Harmonization with Certain Provisions of the Controlled Substances Regulations)

Amendments

1 (1) The definition nécessaire d’essai in subsection 1(2) of the French version of the Cannabis Regulations ^{footnote 1} is repealed.

(2) The definition combination product in subsection 1(2) of the Regulations is replaced by the following:

combination product

means a product, consisting of a device and a prescription drug, that has a drug identification number. (produit mixte)

(3) The definition test kit in subsection 1(2) of the English version of the Regulations is replaced by the following:

test kit

means a kit

• (a) that contains cannabis and an adulterating or denaturing agent;
• (b) that is used to test for cannabis; and
• (c) the contents of which are not intended or likely to be consumed or administered. (trousse d’essai ou nécessaire d’essai)

(4) Paragraph (c) of the definition prescription drug in subsection 1(2) of the Regulations is replaced by the following:

• (c) that has a drug identification number. (drogue sur ordonnance)

(5) Subsection 1(2) of the Regulations is amended by adding the following in alphabetical order:

brand name,

in respect of a prescription drug or a combination product, has the same meaning as in subsection C.01.001(1) of the Food and Drug Regulations. (nom commercial)

common name,

except in Part 7 and section 226.1, has the same meaning as in subsection C.01.001(1) of the Food and Drug Regulations. (nom usuel)

drug identification number

means the identification number assigned under paragraph C.01.014.2(1)(a) of the Food and Drug Regulations. (identification numérique)

former Narcotic Control Regulations

means the regulations made by Order in Council P.C. 1961-1133 of August 9, 1961 and registered as SOR/61-344. (ancien Règlement sur les stupéfiants)

(6) Subsection 1(2) of the French version of the Regulations is amended by adding the following in alphabetical order:

trousse d’essai ou nécessaire d’essai

Trousse qui, à la fois :

• a) contient du cannabis ainsi qu’un agent d’adultération ou de dénaturation;
• b) est utilisée pour le dépistage du cannabis;
• c) ne contient rien qui soit destiné à être consommé ou à être administré ou qui soit susceptible de l’être. (test kit)

2 Subparagraph 4(1)(c)(viii) of the Regulations is replaced by the following:

• (viii) a person to which an exemption has been granted under section 140 of the Act in relation to the cannabis or the class of cannabis that is sold or distributed, or

3 The Regulations are amended by adding the following after section 4:

Distribution for destruction

4.1 (1) For the purposes of subparagraphs 9(1)(a)(i) and (iii) and paragraph 9(1)(b) of the Act, an individual who has cannabis in their possession is authorized to distribute the cannabis, for the purpose of its destruction, directly to one of the persons referred to in paragraphs 224(a) to (c) of the Controlled Substances Regulations if

• (a) the individual obtained the cannabis in accordance with the Act or these Regulations; or
• (b) the individual obtained the cannabis from another individual who they have reasonable grounds to believe obtained it in accordance with the Act or these Regulations.

Deeming — finished product

(2) Cannabis that is distributed in accordance with subsection (1) is deemed to be a finished product, as defined in subsection 1(1) of the Controlled Substances Regulations, that has been returned under those Regulations by an individual for the purpose of destruction.

Controlled Substances Regulations apply

(3) A person to which the cannabis is distributed in accordance with subsection (1) must, in respect of that cannabis, meet the requirements of the Controlled Substances Regulations in respect of the finished product referred to in subsection (2).

4 Subsection 12(2) of the Regulations is replaced by the following:

Responsibilities and knowledge

(2) The master grower is responsible for the cultivation, propagation and harvesting of cannabis and must have sufficient knowledge of the provisions of the Act and these Regulations that are applicable to those activities to properly carry out their duties.

5 Subsection 15(2) of the Regulations is replaced by the following:

Responsibilities and knowledge

(2) The master grower is responsible for the cultivation, propagation and harvesting of cannabis and must have sufficient knowledge of the provisions of the Act and these Regulations that are applicable to those activities to properly carry out their duties.

6 (1) Paragraph 23(2)(a) of the Regulations is replaced by the following:

• (a) have sufficient knowledge of the provisions of the Act and these Regulations that are applicable to the activities authorized by the licence for analytical testing to properly carry out their duties;

(2) Paragraph 23(2)(b) of the English version of the Regulations is replaced by the following:

• (b) have knowledge and experience relevant to their duties; and

(3) Subparagraph 23(2)(c)(i) of the English version of the Regulations is replaced by the following:

• (i) a diploma, certificate or credential awarded by a post-secondary educational institution in Canada in a field or occupation that is relevant to their duties, such as chemistry, biology, pharmaceutical or scientific regulatory affairs, laboratory management or laboratory technician, or

(4) The portion of subparagraph 23(2)(c)(ii) of the Regulations before clause (A) is replaced by the following:

• (ii) a diploma, certificate or credential awarded by a foreign educational institution in a field or occupation referred to in subparagraph (i) and one of the following assessments that establishes the equivalency of the diploma, certificate or credential to one of the documents referred to in that subparagraph:

(5) Clauses 23(2)(c)(ii)(A) and (B) of the French version of the Regulations are replaced by the following:

• (A) une attestation d’équivalence au sens du paragraphe 73(1) du Règlement sur l’immigration et la protection des réfugiés,
• (B) une attestation d’équivalence délivrée par une institution ou une organisation chargée de faire des attestations d’équivalence et reconnue par une province.

7 Subsection 37(2) of the Regulations is replaced by the following:

Responsibilities and knowledge

(2) The responsible person is responsible for the activities conducted under the licence and must have sufficient knowledge of the provisions of the Act and these Regulations that are applicable to those activities to properly carry out their duties.

8 (1) The definitions brand name and common name in section 139 of the Regulations are repealed.

(2) The definitions licensed dealer, qualified person in charge and senior person in charge in section 139 of the Regulations are replaced by the following:

licensed dealer

has the same meaning as in subsection 1(1) of the Controlled Substances Regulations. (distributeur autorisé)

qualified person in charge,

except in paragraph 146(4)(a), means the individual referred to in section 150. (responsable qualifié)

senior person in charge,

except in paragraph 146(4)(a), means the individual referred to in section 149. (responsable principal)

(3) Section 139 of the Regulations is amended by adding the following in alphabetical order:

specialized in destruction

has the same meaning as in subsection 1(1) of the Controlled Substances Regulations. (spécialisé en destruction)

9 (1) Paragraph 143(1)(g) of the Regulations is replaced by the following:

• (g) a pharmacist, if the drug is a prescription drug;

(2) Paragraph 143(1)(i) of the Regulations is replaced by the following:

• (i) a hospital employee, if the drug is a prescription drug;

(3) Paragraphs 143(2)(a) and (b) of the Regulations are replaced by the following:

• (a) they receive a written order that specifies
  • (i) the proper name or common name of the drug or, in the case of a prescription drug, the brand name of the drug and its drug identification number, and
  • (ii) the quantity of the drug to be supplied;
• (b) the order is signed and dated
  • (i) in the case of a prescription drug to be provided to a hospital employee or a practitioner in a hospital, by a pharmacist or practitioner authorized by the individual in charge of the hospital to sign the order, and
  • (ii) in any other case, by the person to which the drug is to be sold; and
• (c) the holder verifies the signature, if it is unknown to them.

(4) Subsection 143(3) of the Regulations is replaced by the following:

Exception — pharmacist and practitioner

(3) It is prohibited for a holder of a cannabis drug licence to sell or distribute

• (a) a prescription drug to a pharmacist who is named in a notice issued under subsection 181(2) or (4); or
• (b) a drug containing cannabis to a practitioner who is named in a notice issued under subsection 189(2) or (4).

10 (1) Subsections 146(4) and (5) of the Regulations are replaced by the following:

Witness — licensed dealer specialized in destruction

(4) The following individuals are qualified to witness the destruction of cannabis by a licensed dealer specialized in destruction:

• (a) the senior person in charge or qualified person in charge, as those terms are defined in subsection 1(1) of the Controlled Substances Regulations, or an alternate qualified person in charge designated under subsection 9(2) of those Regulations; and
• (b) a person who works for or provides services to the licensed dealer specialized in destruction and holds a senior position.

Attestation by witnesses

(5) For each instance in which they destroy cannabis, the holder of a cannabis drug licence or the licensed dealer specialized in destruction, as the case may be, must obtain an attestation signed and dated by two of the witnesses referred to in paragraph (1)(b) or (2)(b) stating that they witnessed the destruction and that the cannabis was destroyed in accordance with a method referred to in paragraph (1)(a) or (2)(a).

(2) Paragraph 146(6)(b) of the Regulations is replaced by the following:

• (b) in the case of a drug containing cannabis,
  • (i) the proper name or common name of the drug or, in the case of a prescription drug, the brand name of the drug and its drug identification number, and
  • (ii) the strength per unit of the drug;

(3) Subsection 146(7) of the Regulations is replaced by the following:

Retention period

(7) The holder of a cannabis drug licence and the licensed dealer specialized in destruction must retain the record and the attestation for at least two years after the day on which the cannabis is destroyed.

11 (1) The portion of subparagraph 150(3)(b)(iii) of the Regulations before clause (A) is replaced by the following:

• (iii) hold a diploma, certificate or credential that is awarded by a foreign educational institution in a field or occupation referred to in subparagraph (ii) and one of the following assessments that establishes the equivalency of the diploma, certificate or credential to one of the documents referred to in that subparagraph:

(2) Clauses 150(3)(b)(iii)(A) and (B) of the French version of the Regulations are replaced by the following:

• (A) une attestation d’équivalence au sens du paragraphe 73(1) du Règlement sur l’immigration et la protection des réfugiés,
• (B) une attestation d’équivalence délivrée par une institution ou une organisation chargée de faire des attestations d’équivalence et reconnue par une province;

(3) Paragraph 150(3)(d) of the Regulations is replaced by the following:

• (d) they have sufficient knowledge of the provisions of the Act and these Regulations that are applicable to the activities authorized by the licence to properly carry out their duties.

(4) Paragraph 150(4)(c) of the English version of the Regulations is replaced by the following:

• (c) the individual has sufficient knowledge acquired from any combination of education, training and work experience to properly carry out their duties.

12 Paragraphs 151(2)(a) to (d) of the French version of the Regulations are amended by replacing “visée à” with “prévue à”.

13 (1) Subparagraph 152(2)(b)(i) of the Regulations is replaced by the following:

• (i) an attestation, signed and dated by the proposed individual, stating that the proposed individual is not ineligible for a reason specified in section 151,

(2) Subparagraph 152(2)(c)(ii) of the Regulations is replaced by the following:

• (ii) an attestation, signed and dated by the senior person in charge, stating that the proposed individual has the knowledge and experience required under paragraphs 150(3)(c) and (d), and

(3) The portion of subparagraph 152(2)(c)(iii) of the French version of the Regulations before clause (A) is replaced by the following:

• (iii) dans le cas où l’individu proposé ne satisfait pas à l’exigence visée au sous-alinéa 150(3)b)(i) :

14 The heading of Division 2 of Part 8 of the Regulations is replaced by the following:

Possession, Pharmacists, Practitioners, Hospitals and Licensed Dealers

15 (1) Paragraph 159(a) of the Regulations is replaced by the following:

• (a) a practitioner who is entitled to practise in the province in which they possess the drug or a holder of a cannabis drug licence, if they require the drug for their business or profession;

(2) Paragraphs 159(c) to (f) of the Regulations are replaced by the following:

• (c) an individual who possesses a quantity of the drug that exceeds the applicable limit under the Act and who
  • (i) has obtained the drug, for their own use or for an animal for which the individual is responsible, from a practitioner or in accordance with a prescription that was not issued or obtained in contravention of these Regulations, or
  • (ii) has imported the drug in accordance with section 195.4;
• (d) an individual who possesses a quantity of the drug that exceeds the applicable limit under the Act and has reasonable grounds to believe that the drug was obtained by another individual in accordance with paragraph (c) if the possession is for the purpose of its return or destruction;
• (e) a licensed dealer, other than a licensed dealer specialized in destruction, if the possession is for the purpose of selling or distributing it to a licensed dealer specialized in destruction;
• (f) a licensed dealer specialized in destruction, if the possession is for the purpose of its destruction;

(3) Section 159 of the Regulations is renumbered as subsection 159(1) and is amended by adding the following:

Possession — prescription drug

(2) The following persons, if they have obtained a prescription drug either in accordance with these Regulations, or from a person that is exempt under section 140 of the Act from the application of subsections 9(1) and (2) and 10(1) and (2) of the Act with respect to that drug, are authorized to possess the drug:

• (a) a pharmacist, if they require the drug for their business or profession; or
• (b) a hospital employee or a practitioner in a hospital.

16 Sections 160 and 161 of the Regulations are replaced by the following:

Possession — quantity allowed

160 Any quantity of drug containing cannabis that an individual is authorized to possess under paragraph 159(1)(c) or (d) is in addition to any other quantity of cannabis that the individual is authorized to possess under the Act.

17 Sections 163 and 164 of the Regulations are replaced by the following:

Exemption — section 21 of Act

163 A person is exempt from the application of section 21 of the Act if they display, refer to or otherwise use the brand name of a prescription drug, or the name of the holder of the drug identification number for a prescription drug, directly or indirectly in a promotion that is used in the sponsorship of a person, entity, event, activity or facility.

Exemption — section 22 of Act

164 A person is exempt from the application of section 22 of the Act if they display on a facility, as part of the name of the facility or otherwise, if the facility is used for a sports or cultural event or activity, the brand name of a prescription drug or the name of the holder of the drug identification number for a prescription drug.

18 Paragraph 170(a) of the Regulations is replaced by the following:

• (a) the brand name and quantity of the drug received;

19 (1) The portion of section 171 of the Regulations before paragraph (a) is replaced by the following:

Sale, distribution and administration

171 Subject to section 174, a pharmacist is authorized to sell, distribute or administer a prescription drug to a person

(2) Paragraph 171(a) of the English version of the Regulations is replaced by the following:

• (a) if the person is exempt under section 140 of the Act with respect to the possession of that drug; or

(3) Subparagraph 171(b)(ii) of the French version of the Regulations is replaced by the following:

• (ii) il vérifie la signature du praticien lorsqu’il ne la reconnaît pas.

20 (1) The portion of subsection 172(1) of the Regulations before paragraph (a) is replaced by the following:

Return and destruction

172 (1) A pharmacist is authorized to sell or distribute a prescription drug, in accordance with a written order, to

(2) Paragraph 172(2)(a) of the Regulations is replaced by the following:

• (a) the brand name, quantity and strength per unit of the drug; and

21 Section 173 of the Regulations is repealed.

22 The portion of subsection 174(1) of the Regulations before paragraph (a) is replaced by the following:

Prohibited activities

174 (1) It is prohibited for a pharmacist to

23 Subsection 175(1) of the Regulations is replaced by the following:

Distribution — hospital

175 (1) Subject to section 174, a pharmacist may distribute a prescription drug to a hospital employee or a practitioner in a hospital in accordance with a written order signed and dated by a pharmacist or practitioner authorized by the individual in charge of the hospital to sign the order.

24 The portion of section 176 of the Regulations before paragraph (a) is replaced by the following:

Security obligations

176 A pharmacist must, with respect to a prescription drug on their premises or for which they are responsible,

25 Section 177 of the Regulations is replaced by the following:

Record keeping

177 (1) A pharmacist who sells, distributes or administers a prescription drug must retain a record of the following information:

• (a) in the case of a sale, distribution or administration to a person in accordance with a written order or prescription,
  • (i) the name of the pharmacist,
  • (ii) the name and address of the pharmacist or practitioner who issued the order or of the practitioner who issued the prescription,
  • (iii) the name and address of the person to which the drug was sold, distributed or administered,
  • (iv) the brand name, quantity and form of the drug,
  • (v) the date on which the drug was sold, distributed or administered, and
  • (vi) in the case of a prescription, the number assigned to it; and
• (b) in the case of a sale, distribution or administration to a person that is exempt under section 140 of the Act with respect to the possession of the drug,
  • (i) the name of the pharmacist,
  • (ii) the name and address of the person to which the drug was sold, distributed or administered,
  • (iii) the brand name, quantity and form of the drug, and
  • (iv) the date on which the drug was sold, distributed or administered.

Non-application

(2) Subsection (1) does not apply to a pharmacist who sells or distributes a prescription drug under subsection 178(1) or 178.1(1).

26 Subsection 178(1) of the Regulations is replaced by the following:

Sale and distribution for emergency purposes

178 (1) Subject to section 174, a pharmacist may sell or distribute a prescription drug for emergency purposes to another pharmacist in accordance with a written order that is signed and dated by the other pharmacist.

27 Section 179 of the Regulations is replaced by the following:

Sale and distribution — no emergency

178.1 (1) Subject to section 174, a pharmacist may, in circumstances other than an emergency, sell or distribute a prescription drug to another pharmacist, in accordance with a written order that is signed and dated by the other pharmacist, if

• (a) they do so for the purpose of fulfilling a prescription received by the other pharmacist; or
• (b) they are ceasing to practise at the pharmacy where the drug is sold or distributed.

Signature

(2) Before selling or distributing the prescription drug, the pharmacist receiving the order must verify the signature if it is unknown to them.

Record keeping

(3) The pharmacist who sells or distributes the prescription drug and the pharmacist to whom it is sold or distributed must each retain a record of the following information:

• (a) in the case of the pharmacist who sells or distributes the drug,
  • (i) their name,
  • (ii) the name and address of the pharmacist to whom they sell or distribute the drug,
  • (iii) the brand name, quantity and form of the drug, and
  • (iv) the date of the sale or distribution of the drug; and
• (b) in the case of the pharmacist to whom the drug is sold or distributed,
  • (i) their name,
  • (ii) the name and address of the pharmacist who sells or distributes the drug to them,
  • (iii) the brand name, quantity and form of the drug, and
  • (iv) the date on which the drug is received.

Retention period

179 (1) Subject to subsections (2) and (3), a pharmacist must ensure that the records that the pharmacist is required to retain under this Part are retained for at least two years after the day on which they are prepared.

Ceasing to practise

(2) If the pharmacist ceases to practise at the pharmacy where the records are prepared, the pharmacist who is responsible for the operations of that pharmacy must ensure that any records for which the two-year retention period has not ended are retained for the remainder of that retention period.

Ceasing operations

(3) If the pharmacy where the pharmacist practises ceases its operations, the person responsible for those operations on the date those operations cease must ensure that any records for which the two-year retention period has not ended are retained for the remainder of that retention period.

28 Paragraph 181(4)(a) of the Regulations is replaced by the following:

• (a) has contravened section 171, subsection 172(1) or (2), section 174, 175 or 176 or subsection 178(1) or 178.1(1) or (2);

29 (1) The portion of subsection 184(1) of the French version of the Regulations before paragraph (a) is replaced by the following:

Retour et destruction

184 (1) Le praticien est autorisé à vendre ou à distribuer une drogue contenant du cannabis aux personnes ci-après conformément à une commande écrite :

(2) Paragraph 184(2)(a) of the Regulations is replaced by the following:

• (a) the quantity and strength per unit of the drug as well as its proper name or common name or, in the case of a prescription drug, its brand name; and

(3) Paragraph 184(3)(a) of the Regulations is replaced by the following:

• (a) its form, quantity and strength per unit as well as its proper name or common name or, in the case of a prescription drug, its brand name;

30 The portion of section 186 of the Regulations before paragraph (a) is replaced by the following:

Record keeping

186 A practitioner who sells or distributes a drug containing cannabis to an individual for self-administration or for administration to an animal must, whether or not the practitioner charges for the drug, retain a record showing the drug’s proper name or common name — or, in the case of a prescription drug, its brand name — and the quantity of the drug sold or distributed, as well as the name and address of the individual to whom and the date on which it was sold or distributed, if the quantity of the drug exceeds

31 Section 187 of the Regulations is replaced by the following:

Retention period

187 (1) Subject to subsections (2) and (3), a practitioner must ensure that the records that the practitioner is required to retain under this Part are retained for at least two years after the day on which they are prepared.

Ceasing to practise

(2) If the practitioner ceases to practise at the place where the records are prepared, the practitioner who is responsible for the operations of that place must ensure that any records for which the two-year retention period has not ended are retained for the remainder of that retention period.

Ceasing operations

(3) If the place where the practitioner practises ceases its operations, the person responsible for those operations on the date those operations cease must ensure that any records for which the two-year retention period has not ended are retained for the remainder of that retention period.

32 (1) The portion of paragraph 189(1)(a) of the Regulations before subparagraph (i) is replaced by the following:

• (a) the following persons must not sell or distribute any drug containing cannabis to the practitioner:

(2) Paragraph 189(2)(e) of the Regulations is replaced by the following:

• (e) the applicable provincial professional regulatory authority for the province in which the practitioner is entitled to practise; and

(3) Paragraphs 189(4)(b) to (d) of the Regulations are replaced by the following:

• (b) has, on more than one occasion, self-administered a drug containing cannabis under a self-directed prescription or order or, in the absence of a prescription or order, contrary to accepted professional practice;
• (c) has, on more than one occasion, distributed or administered a drug containing cannabis to their spouse, common-law partner, parent or child, including a child adopted in fact, contrary to accepted professional practice; or
• (d) is unable to account for the quantity of drugs containing cannabis for which the practitioner was responsible under this Part or Part 9.

(4) Subparagraph 189(5)(c)(iii) of the Regulations is replaced by the following:

• (iii) whether the actions of the practitioner pose a significant risk to public health or public safety, including the risk of any drug containing cannabis being diverted to an illicit market or activity.

33 (1) Subparagraph 191(a)(i) of the Regulations is replaced by the following:

• (i) the brand name and quantity of the drug,

(2) The portion of paragraph 191(b) of the Regulations before subparagraph (ii) is replaced by the following:

• (b) with respect to a prescription drug that is sold, distributed or administered by the hospital,
  • (i) the name of the patient for whom, or the animal for which, the drug was sold, distributed or administered,

34 The portion of section 192 of the Regulations before paragraph (a) is replaced by the following:

Security obligations

192 An individual in charge of a hospital must, with respect to a prescription drug for which the hospital is responsible,

35 (1) The portion of subsection 193(2) of the Regulations before paragraph (a) is replaced by the following:

Inpatients and outpatients

(2) The individual in charge of a hospital may authorize the sale, distribution or administration of a prescription drug only in accordance with a prescription, signed and dated by a practitioner, and only

(2) Paragraph 193(2)(a) of the English version of the Regulations is replaced by the following:

• (a) in the case of administration, to an individual or an animal under treatment as an inpatient or outpatient of the hospital; or

(3) The portion of subsection 193(3) of the Regulations before paragraph (a) is replaced by the following:

Distribution or sale in an emergency

(3) Despite subsection (2), for emergency purposes, the individual in charge of a hospital may authorize the sale or distribution of a prescription drug to

(4) Subparagraphs 193(3)(a)(i) and (ii) of the Regulations are replaced by the following:

• (i) the drug is sold or distributed in accordance with a written order signed and dated by a pharmacist or practitioner authorized by the individual in charge of the other hospital to sign the order, and
• (ii) the person that sells or distributes the drug verifies the signature of the pharmacist or practitioner, if that signature is unknown to the person;

(5) Subparagraphs 193(3)(b)(i) and (ii) of the Regulations are replaced by the following:

• (i) the drug is sold or distributed in accordance with a written order signed and dated by a pharmacist or practitioner who is authorized by the individual in charge of the other hospital to sign the order, and
• (ii) the person that sells or distributes the drug verifies the signature of the pharmacist or practitioner, if that signature is unknown to the person; and

(6) Paragraph 193(3)(c) of the English version of the Regulations is replaced by the following:

• (c) an individual who is exempt under section 140 of the Act with respect to the drug and who is employed in a research laboratory in the hospital for the purpose of research.

36 (1) The portion of subsection 194(1) of the Regulations before paragraph (a) is replaced by the following:

Return and destruction

194 (1) Despite subsection 193(2), the individual in charge of a hospital may authorize the sale or distribution of a prescription drug, in accordance with a written order, to

(2) Paragraph 194(2)(a) of the Regulations is replaced by the following:

• (a) the brand name, quantity and strength per unit of the drug; and

(3) Paragraph 194(3)(b) of the English version of the Regulations is replaced by the following:

• (b) the name and address of the person to which it was sold or distributed; and

37 Section 195 of the Regulations is replaced by the following:

Retention period

195 (1) Subject to subsections (2) and (3), an individual in charge of a hospital must ensure that the records that the individual is required to retain under this Part are retained for at least two years after the day on which they are prepared.

Ceasing to act

(2) If the individual in charge of the hospital ceases to act in that capacity at the hospital where the records are prepared, the individual who replaces that individual must ensure that any records for which the two-year retention period has not ended are retained for the remainder of that retention period.

Ceasing operations

(3) If the hospital ceases its operations, the person responsible for those operations on the date those operations cease must ensure that any records for which the two-year retention period has not ended are retained for the remainder of that retention period.

Licensed Dealers

Record keeping — drug received

195.1 A licensed dealer that receives a drug containing cannabis must enter the following in a record retained for such purposes:

• (a) the proper name or common name of the drug or, in the case of a prescription drug, its brand name and drug identification number;
• (b) the form, quantity and strength per unit of the drug received;
• (c) the name and address of the person from which the drug was received; and
• (d) the date of receipt.

Sale or distribution for destruction

195.2 (1) A licensed dealer, other than a licensed dealer specialized in destruction, may sell or distribute a drug containing cannabis, in accordance with a written order, to a licensed dealer specialized in destruction if the drug is sold or distributed for the purpose of its destruction.

Written order

(2) The written order must contain

• (a) the proper name or common name of the drug or, in the case of a prescription drug, its brand name and drug identification number;
• (b) the quantity and strength per unit of the drug; and
• (c) an attestation that states that the sole purpose of the order is the destruction of the drug and that is signed and dated by, or on behalf of, the licensed dealer specialized in destruction.

Record keeping

(3) The licensed dealer referred to in subsection (1) that sells or distributes the drug must prepare a record that sets out

• (a) the proper name or common name of the drug or, in the case of a prescription drug, its brand name and drug identification number;
• (b) the form, quantity and strength per unit of the drug;
• (c) the name and address of the person to which it was sold or distributed; and
• (d) the date on which it was sold or distributed.

Retention period

195.3 The licensed dealer must retain the records referred to in section 195.1 and subsection 195.2(3) for at least two years after the day on which they are prepared.

DIVISION 3

Importation and Exportation by Travellers

Importation

195.4 On entering Canada, an individual may import a drug containing cannabis that is in their actual possession or that forms part of their baggage if

• (a) the individual is importing the drug
  • (i) for their own use,
  • (ii) for the use and on behalf of an accompanying individual, or
  • (iii) for administration to an animal for which the individual is responsible and that is accompanying the individual;
• (b) the drug is declared to a customs officer at the port of entry into Canada;
• (c) the drug is in a container obtained from a health care provider and carrying a label on which the following information appears:
  • (i) the name of the individual for whom, or the animal for which, the drug was lawfully obtained,
  • (ii) the name of the health care provider who authorized the drug to be obtained,
  • (iii) the proper name or common name of the drug or, in the case of a prescription drug, its brand name and, if any, its drug identification number,
  • (iv) the form, quantity and strength per unit of the drug, and
  • (v) the daily dose authorized by the health care provider; and
• (d) the imported quantity of the drug does not exceed a 90-day supply required to treat a condition, based on the daily dose shown on the label.

Exportation

195.5 On departing Canada, an individual may export a drug containing cannabis that is in their actual possession or that forms part of their baggage if

• (a) the individual is exporting the drug
  • (i) for their own use,
  • (ii) for the use and on behalf of an accompanying individual, or
  • (iii) for administration to an animal for which the individual is responsible and that is accompanying the individual;
• (b) the drug is in a container obtained from a health care provider and carrying a label on which the following information appears:
  • (i) the name of the individual for whom, or the animal for which, the drug was lawfully obtained,
  • (ii) the name of the health care provider who authorized the drug to be obtained,
  • (iii) the proper name or common name of the drug or, in the case of a prescription drug, its brand name and, if any, its drug identification number,
  • (iv) the form, quantity and strength per unit of the drug, and
  • (v) the daily dose authorized by the health care provider; and
• (c) the exported quantity of the drug does not exceed a 90-day supply required to treat a condition, based on the daily dose shown on the label.

38 Section 196 of the Regulations is repealed.

39 Sections 198 and 199 of the Regulations are replaced by the following:

Exemption — section 21 of Act

198 A person is exempt from the application of section 21 of the Act if they display, refer to or otherwise use the brand name of a combination product, or the name of the holder of the drug identification number for the product, directly or indirectly in a promotion that is used in the sponsorship of a person, entity, event, activity or facility.

Exemption — section 22 of Act

199 A person is exempt from the application of section 22 of the Act if they display on a facility, as part of the name of the facility or otherwise, if the facility is used for a sports or cultural event or activity, the brand name of a combination product or the name of the holder of the drug identification number for the product.

40 Subparagraphs 205(c)(iv) and (v) of the Regulations are replaced by the following:

• (iv) in the case of a drug containing cannabis, other than a prescription drug, the proper name or common name of the drug,
• (v) in the case of a prescription drug, the brand name of the drug and its identification number,
• (vi) the quantity of the cannabis, and
• (vii) the percentages of THC w/w and CBD w/w of the cannabis, except in the case of cannabis plants and cannabis plant seeds;

41 Subparagraphs 209(c)(iv) and (v) of the Regulations are replaced by the following:

• (iv) in the case of a drug containing cannabis, other than a prescription drug, the proper name or common name of the drug,
• (v) in the case of a prescription drug, the brand name of the drug and its drug identification number,
• (vi) the quantity of the cannabis, and
• (vii) the percentages of THC w/w and CBD w/w of the cannabis, except in the case of cannabis plants and cannabis plant seeds.

42 Subparagraphs 214(c)(iv) and (v) of the Regulations are replaced by the following:

• (iv) in the case of a drug containing cannabis, other than a prescription drug, the proper name or common name of the drug,
• (v) in the case of a prescription drug, the brand name of the drug and its drug identification number,
• (vi) the quantity of the cannabis, and
• (vii) the percentages of THC w/w and CBD w/w of the cannabis, except in the case of cannabis plants and cannabis plant seeds;

43 Subparagraphs 218(c)(iv) and (v) of the Regulations are replaced by the following:

• (iv) in the case of a drug containing cannabis, other than a prescription drug, the proper name or common name of the drug,
• (v) in the case of a prescription drug, the brand name of the drug and its drug identification number,
• (vi) the quantity of the cannabis, and
• (vii) the percentages of THC w/w and CBD w/w of the cannabis, except in the case of cannabis plants and cannabis plant seeds.

44 Paragraph 224(2)(c) of the Regulations is replaced by the following:

• (c) in the case of a drug containing cannabis,
  • (i) the proper name or common name of the drug or, in the case of a prescription drug, the brand name of the drug and its drug identification number, and
  • (ii) the strength per unit of the drug.

45 Paragraph 225(2)(c) of the Regulations is replaced by the following:

• (c) in the case of a drug containing cannabis,
  • (i) the proper name or common name of the drug or, in the case of a prescription drug, the brand name of the drug and its drug identification number, and
  • (ii) the strength per unit of the drug.

46 Paragraph 226(1)(g) of the Regulations is replaced by the following:

• (g) in the case of a drug containing cannabis,
  • (i) the proper name or common name of the drug or, in the case of a prescription drug, the brand name of the drug and its drug identification number, and
  • (ii) the form of the drug and its strength per unit; and

47 Paragraph 227(1)(g) of the Regulations is replaced by the following:

• (g) in the case of a drug containing cannabis,
  • (i) the proper name or common name of the drug or, in the case of a prescription drug, the brand name of the drug and its drug identification number, and
  • (ii) the form of the drug and its strength per unit;

48 Paragraph 229(1)(a) of the Regulations is replaced by the following:

• (a) a description of the cannabis, including,
  • (i) in the case of a drug containing cannabis, other than a prescription drug, the proper name or common name of the drug,
  • (ii) in the case of a prescription drug, the brand name of the drug and its drug identification number,
  • (iii) in any other case, the brand name of the cannabis, if applicable;

49 (1) Subparagraphs 237(1)(a)(ii) to (iv) of the Regulations are replaced by the following:

• (ii) in the case of a drug containing cannabis, other than a prescription drug, the proper name or common name of the drug,
• (iii) in the case of a prescription drug, the brand name of the drug and its drug identification number,
• (iv) the quantity used and, if applicable, the lot or batch number,
• (v) the date on which it is used, and
• (vi) the purpose and a brief description of the activity;

(2) Subparagraph 237(1)(b)(i) of the Regulations is replaced by the following:

• (i) its description, including, in the case of a drug containing cannabis, the proper name or common name of the drug,

50 Paragraph 247(2)(a) of the Regulations is replaced by the following:

• (a) a description of the cannabis, including,
  • (i) in the case of a drug containing cannabis, other than a prescription drug, the proper name or common name of the drug,
  • (ii) in the case of a prescription drug, the brand name of the drug and its drug identification number,
  • (iii) in any other case, the brand name of the cannabis, if applicable;

51 (1) Paragraph 255(a) of the Regulations is replaced by the following:

• (a) subject to subparagraph 261(2)(a)(i), a registration number has been issued for the test kit and the number has not been cancelled;

(2) Clause 255(b)(ii)(A) of the Regulations is replaced by the following:

• (A) the name and address of the manufacturer or assembler or, if applicable, of the person for which the test kit was manufactured or assembled further to a custom order, and

(3) Paragraph 255(c) of the English version of the Regulations is replaced by the following:

• (c) the test kit is sold, imported or exported for a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose.

52 Paragraph 256(b) of the English version of the Regulations is replaced by the following:

• (b) distribute it for a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose.

53 (1) Paragraphs 258(1)(b) and (c) of the Regulations are replaced by the following:

• (b) a detailed description of the design and construction of the test kit;
• (c) a description of the proposed use of the test kit;

(2) Paragraph 258(1)(e) of the Regulations is replaced by the following:

• (e) with respect to any other substance contained in the test kit, its name, form and quantity; and

(3) Subsection 258(2) of the Regulations is replaced by the following:

Signature and attestation

(2) The application must

• (a) be signed and dated by the individual authorized by the applicant for that purpose; and
• (b) include an attestation by that individual that all of the information provided in support of the application is correct and complete to the best of their knowledge.

54 Sections 260 and 261 of the Regulations are replaced by the following:

Issuance of a registration number

260 (1) Subject to section 260.1, the Minister must, after examining the information and documents required under sections 258 and 259, issue to the applicant a document that sets out a registration number for the test kit if the Minister determines that the test kit will be used only for a medical, laboratory, industrial, educational, law administration or enforcement, or research purpose.

Alteration of documents

(2) A person must not alter or deface in any manner the document that sets out the registration number.

Refusal

260.1 The Minister must refuse to issue a registration number for a test kit if the Minister has reasonable grounds to believe that

• (a) the test kit poses a risk to public health or safety, including the risk of the cannabis in the test kit being diverted to an illicit market or activity, because
  • (i) the total amount of the cannabis is too high, or
  • (ii) the adulterating or denaturing agent in the test kit is not likely to prevent or deter the consumption or administration of the cannabis; or
• (b) the test kit will be used for a purpose other than one set out in subsection 260(1).

Cancellation

261 (1) The Minister must cancel the registration number of a test kit if

• (a) the Minister receives a notice from the person to which the document that sets out the registration number was issued, stating that manufacture or assembly of the test kit has ceased; or
• (b) the Minister has reasonable grounds to believe that one of the circumstances referred to in paragraph 260.1(a) or (b) exists.

Effect of cancellation

(2) The following rules apply when the registration number of a test kit is cancelled:

• (a) in the case of a test kit manufactured or assembled before a cancellation under paragraph (1)(a),
  • (i) the sale, import and export remain authorized, and
  • (ii) the registration number must remain on the label; and
• (b) in the case of a test kit manufactured or assembled either before or after a cancellation under paragraph (1)(b), the registration number must not be displayed on the label.

55 Section 263 of the Regulations is repealed.

56 The Regulations are amended by replacing “a declaration” and “declaration” with “an attestation” and “attestation”, respectively, in the following provisions:

• (a) paragraph 20(2)(c);
• (b) paragraph 24(2)(c);
• (c) paragraph 33(2)(c);
• (d) paragraph 34(2)(b);
• (e) subparagraph 152(2)(c)(i); and
• (f) paragraph 153(2)(b).

57 The Regulations are amended by replacing “licensed dealer” with “licensed dealer specialized in destruction” in the following provisions:

• (a) paragraph 143(1)(f); and
• (b) the portion of subsection 146(2) before paragraph (a) and the portion of subsection 146(6) before paragraph (a).

58 The Regulations are amended by replacing “a written statement that affirms” with “an attestation that states” in the following provisions:

• (a) paragraph 172(2)(b);
• (b) paragraph 184(2)(b); and
• (c) paragraph 194(2)(b).

59 The Regulations are amended by replacing “professional licensing authority” with “professional regulatory authority” in the following provisions:

• (a) the portion of section 180 before paragraph (a);
• (b) paragraphs 181(2)(d) and (e), (3)(b) and (5)(a);
• (c) paragraph 182(1)(b);
• (d) the portion of section 188 before paragraph (a);
• (e) paragraphs 189(2)(f), (3)(b) and (5)(a);
• (f) paragraph 190(1)(b);
• (g) the definition provincial professional licensing authority in subsection 264(1);
• (h) subsection 277(1);
• (i) paragraphs 299(1)(a) and (b);
• (j) the portion of subsection 300(1) before paragraph (a);
• (k) paragraph 305(1)(a), the portion of paragraph 305(1)(b) before subparagraph (i) and paragraphs 305(1)(c) to (e);
• (l) the portion of subsection 328(1) before paragraph (a) and the portion of subsection 328(2) before paragraph (a);
• (m) the portion of paragraph 333(a) before subparagraph (i) and the portion of paragraph 333(b) before subparagraph (i);
• (n) paragraphs 335(2)(b), (3)(d) and (e) and (5)(a);
• (o) paragraph 336(1)(b);
• (p) the portion of paragraph 343(a) before subparagraph (i) and the portion of paragraph 343(b) before subparagraph (i);
• (q) paragraphs 344(1)(d) and (e), (2)(b) and (4)(a); and
• (r) paragraph 345(1)(b).

60 The Regulations are amended by replacing “Narcotic Control Regulations” with “former Narcotic Control Regulations” in the following provisions:

• (a) clause 180(a)(ii)(D);
• (b) subparagraphs 181(3)(c)(iii) and (5)(c)(ii);
• (c) clause 188(a)(ii)(D);
• (d) subparagraphs 189(3)(c)(iii) and (5)(c)(ii);
• (e) clause 333(a)(iii)(D) and subparagraph 333(a)(iv);
• (f) subparagraph 335(2)(c)(v) and paragraph 335(4)(e);
• (g) clause 343(a)(iii)(D) and subparagraph 343(a)(iv);
• (h) paragraph 344(3)(c);
• (i) clause 353(1)(a)(iii)(D) and subparagraph 353(1)(a)(iv);
• (j) subsections 355(1) and (2) and the heading of column 1 of the table to section 355; and
• (k) subsections 361(2) and (3).

61 The French version of the Regulations is amended by replacing “nécessaire”, “nécessaire d’essai” and “nécessaires d’essai” with “trousse”, “trousse d’essai” and “trousses d’essai”, respectively, with any necessary modifications, in the following provisions:

• (a) paragraph 4(1)(b);
• (b) subsection 19(4);
• (c) paragraph 22(1)(b);
• (d) the heading of Part 13;
• (e) sections 253 and 254;
• (f) the portion of section 255 before paragraph (a), the portion of paragraph 255(b) before subparagraph (i), the portion of subparagraph 255(b)(ii) before clause (A) and paragraph 255(c);
• (g) sections 256 and 257;
• (h) the portion of subsection 258(1) before paragraph (b), the portion of paragraph 258(1)(d) before subparagraph (i) and paragraph 258(1)(f);
• (i) the portion of section 262 before paragraph (a); and
• (j) the portion of item 3 of the table to section 355 in column 1.

62 The French version of the Regulations is amended by replacing “imposer” with “infliger” in the following provisions:

• (a) subparagraphs 151(1)(a)(ii) and (b)(ii);
• (b) subparagraphs 152(2)(b)(ii) and (iii);
• (c) paragraphs 311(2)(c) and (d); and
• (d) subparagraph 312(4)(c)(i) and paragraph 312(4)(d).

63 The English version of the Regulations is amended by replacing “a statement” and “statement” with “an attestation” and “attestation”, respectively, in the following provisions:

• (a) subsections 229(2) and (3);
• (b) subsection 273(3);
• (c) the portion of paragraph 279(2)(g) before subparagraph (i), subparagraphs 279(2)(g)(iii), (v) and (vi), the portion of paragraph 279(3)(e) before subparagraph (i) and subparagraphs 279(3)(e)(v) and (vi);
• (d) the portion of paragraph 285(2)(e) before subparagraph (i) and subparagraphs 285(2)(e)(iii) and (iv);
• (e) section 307; and
• (f) subsection 312(5).

64 The English version of the Regulations is amended by replacing “professional licensing authority” with “professional regulatory authority” in the following provisions:

• (a) subsection 299(4); and
• (b) the portion of subsection 300(2) before paragraph (a), the portion of subsection 300(3) before paragraph (a) and subsections 300(4) to (8).

Coming into Force

65 These Regulations come into force on October 1, 2026.

N.B. The Regulatory Impact Analysis Statement for these Regulations appears following SOR/2025-242, Controlled Substances Regulations.